English | Español

Johnson & Johnson
Press release submission | May 21, 2021

RYBREVANT™ (amivantamab-vmjw) Receives FDA Approval as the First Targeted Treatment for Patients with Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations
Press release submission | Dec 20, 2019

JOHNSON & JOHNSON: Acquires TARIS Biomedical with Focus on Transforming the Treatment of Bladder Cancer

Press release submission | Jun 14, 2019

JOHNSON & JOHNSON: Janssen reports top-line Phase 3 results for TREMFYA® (guselkumab) in adults with active psoriatic arthritis

Trending
Patient Daily | Sep 3, 2025

Top healthcare marketing experts to present at AOCOO-HNS 2025 virtual mid-year symposium, led by Greg Caesar of Medfluence Advisors
+ Pharmaceuticals
Patient Daily | Sep 4, 2025

PhRMA CEO on 340B abuse: ‘Big hospitals are abusing the 340B program to markup medicine prices’
+ Pharmaceuticals
Patient Daily | Sep 2, 2025

Fmr. Gov. Dean on 340B: ‘There's no actual requirement for hospitals to pass along the savings’
+ Pharmaceuticals
Patient Daily | Aug 29, 2025

Deputy VP of Public Affairs of PhRMA on 340B: ‘Over 80% of all rural hospital beds were actually in urban hospitals’